RxDoctor Payments Data

Thomas Headstream, MD

Internal Medicine · Abilene, TXNPI 1053300863

Payments from drug & device makers

$746,416in general payments, 2019–2025

Across 52 payments — averaging $14,354 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$314K
  • AstraZeneca$220K
  • Currax Pharmaceuticals LLC$184K
  • Vertex$21K
  • Mylan Inc.$8K
  • Inspire Medical Systems, Inc.$104
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$213100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746,416 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$470,995
Medicare patients
1,916
Services billed
27,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$64,673
EliquisApixaban52$56,269
FarxigaDapagliflozin Propanediol37$34,698
JardianceEmpagliflozin19$25,566
OzempicSemaglutide13$24,688
Tresiba Flextouch U-200Insulin Degludec14$24,582
LinzessLinaclotide18$18,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,101
Repatha SureclickEvolocumab16$13,368
MyrbetriqMirabegron13$11,149
EntrestoSacubitril/Valsartan14$9,304
XareltoRivaroxaban11$6,135
MovantikNaloxegol Oxalate12$4,692
Celecoxib38$2,101
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$219,683$34,69837 claims
Novo NordiskOzempic$19$24,68813 claims
AbbVieLinzess$24$18,10218 claims
Mylan Inc.Atorvastatin Calcium$8,067$39259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →